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ORIGINAL ARTICLE

PTPRO represses ERBB2-driven breast oncogenesis by
dephosphorylation and endosomal internalization of ERBB2
H Dong1,9, L Ma2,9, J Gan1, W Lin1, C Chen1, Z Yao1, L Du1, L Zheng1, C Ke1, X Huang3, H Song4, R Kumar5, SC Yeung1,6,7
and H Zhang1,8
The plasma membrane-associated tyrosine phosphatase PTPRO is frequently transcriptionally repressed in cancers and signiﬁes
poor prognosis of breast cancer patients. In this study, deletion of Ptpro in MMTV-Erbb2 transgenic mice dramatically shortened the
mammary tumor latency and accelerated tumor growth due to loss of Ptpro within the breast cancer cells but not in surrounding
tissue as conﬁrmed by hetero-transplantation studies. Both in vitro and in vivo data demonstrated that the phosphatase activity was
required for the inactivation of ERBB2 and its downstream signaling. PTPRO regulated the phosphorylation status of ERBB2 at
Y1248. Co-immunoprecipitation and proximity ligation assay (Duolink) indicated that PTPRO directly physically interacted with
ERBB2. Moreover, PTPRO phosphatase activity shortened the half-life of ERBB2 by increasing endocytotic degradation. PTPRO
reexpression by demethylation treatment using 5-azacytidine reduced the proliferation and colony formation potential in ERBB2positive breast cancer cells. Taken together, PTPRO inhibited ERBB2-driven breast cancer through dephosphorylation leading to
dual effects of ERBB2 signaling suppression and endosomal internalization of ERBB2, Therefore, reexpression of PTPRO may be a
potential therapy for ERBB2-overexpressing breast cancer.
Oncogene advance online publication, 27 June 2016; doi:10.1038/onc.2016.213

INTRODUCTION
Dysregulation of the epidermal growth factor receptors (EGFRs;
that is, type I receptor tyrosine kinases (RTKs): ERBB1 (EGFR),
ERBB2 (HER2), ERBB3 and ERBB4) drives the development and
progression of a wide range of cancers.1 Recently, transcriptomewide array-based analyses have been used to classify human
breast cancer into four main molecular types: luminal A, luminal B,
ERBB2-enriched and basal-like.1 ERBB2-enriched breast cancers
with ERBB2 ampliﬁcation account for approximately a quarter of all
breast cancer and is associated with poor prognosis.1–4 Despite
the clinical beneﬁts resulted from ERBB2-targeted therapeutics, a
substantial percentage of ERBB2-overexpressing cancer fail to
respond or develop secondary resistance to the current targeted
treatments.2–4 Thus, for a complete understanding of ERBB2
functions, it is critical to identify the novel mechanistic control of
ERBB2 signaling, which will advance the intervention and
diagnosis for ERBB2-positive cancers.
Reversible phosphorylation of a speciﬁc tyrosine residue is
governed by the balanced action of PTKs and protein tyrosine
phosphatases (PTPs). Speciﬁcally in ERBB2-overexpressing breast
cancer, ERBB2 dimerization initiates phosphorylation on tyrosine
residues in the cytoplasmic tail of ERBB2,5,6 resulting in
activation of downstream signaling that drives tumor growth.7
Dysregulation of PTPs has been recognized as an important
cause of cancers.8–10 PTP receptor type O (PTPRO, also known
as GLEPP1) is a member of the transmembrane receptor family

of PTPs that is phylogenetically on a branch of the tyrosine
phosphatome distinct from other PTPs.11–17 Besides its functions
in embryonic development, immune response and neuron
differentiation,18,19 PTPRO has been assumed to act as a putative
tumor suppressor in several cancer types.20–23 We recently
presented evidence that the DNA methylation status of PTPRO is
a prognostic factor in ERBB2-positive breast cancer.24 However,
the inherent role of PTPRO in oncogenesis has not been
established in physiologically relevant whole animal models.
The current knowledge gaps also include the following: the
speciﬁc tyrosine residue of ERBB2 that is selectively dephosphorylated by PTPRO is unknown; the mechanism by which
PTPRO inhibits ERBB2-driven tumorigenesis remains largely
unknown; the potential of PTPRO as a therapeutic target in
breast cancer has not been evaluated.
In this study, we investigated these unknown questions,
and discovered that the loss of Ptpro resulted in ampliﬁed
ERBB2 oncogenic signaling, feeding into cancerous phenotypes
in genetic models and ERBB2-overexpressing human breast
tumors. Meanwhile, we discovered the novel mechanisms
responsible for tumor suppression by PTPRO, which involved
dephosphorylation leading to not only blockade of ERBB2
signaling but also endocytotic degradation. Further, we revealed
the therapeutic potential of reexpression of PTPRO by demethylation treatment.
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RESULTS
Ptpro deletion enhanced mammary tumorigenesis in MMTV-Erbb2
transgenic mice
The major knowledge gap about the role of Ptpro in
carcinogenesis is the lack of in vivo evidence. To validate the
tumor-suppressor role of PTPRO, we examined the inﬂuence of
Ptpro knockout (Ptpro− / −) on MMTV-Erbb2-driven mammary
tumorigenesis in mice. To minimize the variability of tumor
formation due to strain difference and heterogeneity of genetic
background, we ﬁrst obtained the Ptpro− / − genotype in a nearpure FVB/N genetic background (99.90% FVB/N) by backcrossing
Ptpro− / − mice to FVB/N mice for 10 generations (see the Methods
for details). No spontaneous mammary tumors were observed in
30 virgin Ptpro− / − female mice and 32 Ptpro− / − breeding dames
with multiple pregnancies after follow-up periods of up to 2 years.
This suggested that loss of Ptpro alone might not be sufﬁcient to
induce breast tumorigenesis. We investigated the inﬂuence of
deleting Ptpro on Erbb2-driven mammary gland tumorigenesis by
crossing MMTV-Erbb2 mice (100% FVB/N) with Ptpro− / −
mice (99.90% FVB/N). We compared breast tumorigenesis in
Ptpro− / −/MMTV-Erbb2 with Ptpro+/+/MMTV-Erbb2 mice. In a longitudinal study, palpable mammary tumors were detected between
26 and 49 weeks of age in 35 Ptpro+/+/MMTV-Erbb2 virgin female
mice (one mouse was lost soon after genotyping); in contrast,
palpable tumors were detected in 36 Ptpro− / −/MMTV-Erbb2 virgin
female mice between 17 and 34 weeks of age (Figure 1a). The
median time to detection of breast tumors was signiﬁcantly
shorter in Ptpro− / −/MMTV-Erbb2 compared with Ptpro+/+/MMTVErbb2 (median: 27 weeks vs 36 weeks, respectively; P o 0.001, log
rank test). All the mice were killed at 9 weeks after tumor
detection. The dissected index tumors in Ptpro− / −/MMTV-Erbb2
mice weighed signiﬁcantly more than those in Ptpro+/+/MMTVErbb2 mice at the same time point after tumor detection
(P = 0.017; Figure 1b and Supplementary Figure 1A). To compare
the rate of tumor progression, we measured the tumor sizes for
9 weeks since detection. Tumor volumes from week 5 to week 9 in
the Ptpro− / −/MMTV-Erbb2 group were signiﬁcantly larger than the
corresponding volumes in the Ptpro+/+/MMTV-Erbb2 group
(Figure 1c). We also documented the number of tumors at
9 weeks after the ﬁrst tumor was detected. Together, deletion
of Ptpro remarkably accelerated Erbb2-driven mammary tumorigenesis, validating the long suspected tumor-suppressor
activity of Ptpro in a whole animal model of breast cancer for
the ﬁrst time.
Cell proliferation, as judged by IHC for phospho-S10-histone H3
(phos-H3) and PCNA in sections of dissected tissues, was
signiﬁcantly enhanced in Ptpro− / −/MMTV-Erbb2 vs Ptpro+/+/
MMTV-Erbb2 mice (12% vs 6% phos-H3-positive cells, and 23%
vs 9% PCNA-positive cells, respectively; P o 0.001 for both;
Figure 1d). However, there was no statistically signiﬁcant
difference in the level of apoptosis between the two genotypes
(Figure 1d). Thus, genetic deletion of Ptpro accelerated the growth
rate of Erbb2-driven mammary tumors primarily through stimulating cell proliferation.
In a cross-sectional study of 24-week-old mice of these
two genotypes (ﬁve mice per group), whole-mount analysis
revealed a lower degree of mammary epithelial hyperplasia
in Ptpro+/+/MMTV-Erbb2 glands as compared with Ptpro− / −/
MMTV-Erbb2 (Figure 1e). We also noticed more mitotic cells
in Ptpro− / −/MMTV-Erbb2 tumors as compared with Ptpro+/+/
MMTV-Erbb2 tumors in 32-week-old mice (Supplementary
Figure 1B). In brief, prevalence of advanced lesions and tumors
in Ptpro− / −/MMTV-Erbb2 mice were consistent with the accelerated tumorigenesis due to Ptpro deletion.
To investigate whether the observed accelerated breast
tumorigenesis in Ptpro− / −/MMTV-Erbb2 mice was primarily due
to loss of Ptpro within the mammary tumor or a consequence
Oncogene (2016) 1 – 13

of possible off-target effects on systemic circulating factors or
non-cancerous host tissues, we transplanted mammary epithelial
tissues from both genotypes of Erbb2 transgenic mice when
30 weeks of age. One million primary cells from two genotypic
mouse tumors were implanted under the dorsal skin of
female nude mice at the right and left ﬂanks, respectively.
Ptpro− / −/MMTV-Erbb2 breast cells developed into palpable tumors
faster than the Ptpro+/+/MMTV-Erbb2 implanted in the same
mouse after implantation (P = 0.043, two-sided paired t-test;
Figure 1f). The excised Ptpro− / −/MMTV-Erbb2 tumors were
signiﬁcantly heavier than the Ptpro+/+/MMTV-Erbb2 tumors when
the mice were killed at 6 weeks after tumor appearance (P = 0.047,
two-sided paired t-test; Figure 1g). These results indicated that the
accelerated mammary tumor development in Ptpro− / −/MMTVErbb2 mice was not an off-target consequence due to loss of Ptpro
in the whole mouse. Collectively, these in vivo data demonstrated
that loss of Ptpro in mammary epithelium caused acceleration of
Erbb2-driven breast carcinogenesis and progression.
PTPRO selectively dephosphorylated ERBB2 at Y1248
Although it is known PTPRO can dephosphorylate ERBB2,25 the
speciﬁc tyrosine residue of ERBB2 that is selectively dephosphorylated by PTPRO is unknown. We thus performed
co-immunoprecipitation studies using the SKBR3 cell line transfected with empty vector or PTPRO vector with or without
heregulin to stimulate ERBB2 signaling. Precipitated proteins were
separated by SDS–polyacrylamide gel electrophoresis followed
by immunoblotting with anti-PTPRO, anti-p-ERBB2 (Y877),
anti-p-ERBB2 (Y1112), anti-p-ERBB2 (Y1139), anti-p-ERBB2
(Y1196), anti-p-ERBB2 (Y1221) or anti-p-ERBB2 (Y1248) and antiERBB2 antibodies (Figure 2a). The ERBB2 associated with
immunoprecipitated PTPRO had detectable phosphorylation at
several phosphorylation sites but not at Y1248. These data
identiﬁed that PTPRO dephosphorylated ERBB2 at Y1248.
Further, we used proximity ligation assay26 to detect whether
there is a direct intermolecular interaction between PTPRO and
ERBB2. SKBR3 cells were ﬁxed and incubated with anti-ERBB2 and
anti-PTPRO antibodies, followed by Duolink reaction. The results
showed that PTPRO and ERBB2 directly interacted at the cell
membrane and in the cytoplasm of cancer cells, while knocking
down either PTPRO or ERBB2 abolished the interaction (Figure 2b).
Together, we for the ﬁrst time identiﬁed the speciﬁc tyrosine site
of ERBB2 dephosphorylated by PTPRO and the subcellular
locations where direct interaction between PPTRO and ERBB2
occurs.
Loss of PTPRO phosphatase activity mimicked PTPRO deletion,
leading to increased tumor cell growth
We next examined the cellular mechanisms by which deletion of
Ptpro enhanced Erbb2-dependent growth and tumorigenesis. To
investigate whether the PTPRO could regulate ERBB2 cellular
activities at endogenous expression level, we generated mouse
embryonic ﬁbroblasts (MEFs) derived from two genotypic mice
and stably transfected them with plasmid FUGW-Erbb2 (Figure 3a).
The growth rate was signiﬁcantly higher in Erbb2/Ptpro− / − MEFs
than in Erbb2/Ptpro+/+ MEFs at 48 h (P = 0.025) and 72 h (P = 0.002;
Figure 3b). Further, Erbb2/Ptpro− / − MEFs also showed increased
colony formation compared with Erbb2/Ptpro+/+MEFs (P = 0.005;
Figure 3c). Flow cytometry assay revealed that the percentage of
cells in the G1 phase decreased to the much lower level in Erbb2/
Ptpro− / − MEFs and this was accompanied by a concomitant
increase of accumulated cells in the S phase (Figure 3d), thus
indicating blocked cell cycle by PTPRO expression. Meanwhile,
Annexin-V-ﬂuorescein isothiocyanate (FITC) and propidium iodide
(PI) dual staining assay did not show any difference in apoptosis
between the Erbb2/Ptpro+/+ and Erbb2/Ptpro− / − MEFs (Figure 3e).
© 2016 Macmillan Publishers Limited
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Figure 1. Ptpro deﬁciency facilitated MMTV-Erbb2-induced mammary tumorigenesis. (a) Kaplan–Meier plots of tumor-free survival in
Ptpro+/+/MMTV-Erbb2 and Ptpro− / −/MMTV-Erbb2 mice. (b) Representative images of tumors from all of the Ptpro− / −/MMTV-Erbb2 mice and
littermate control (left). Harvested tumor weights were determined (right). (c) Tumor volumes were measured at the indicated weeks.
(d) Representative images of immunohistochemistry detection of pH3 and PCNA, and TUNEL in mouse tumors of Ptpro− / −/MMTV-Erbb2 and
littermate control (left). Bar charts represent the quantiﬁcation of staining (right). Samples shown are representative of three independent
experiments (n = 5 per genotype). Error bars indicate s.e.m. *Po0.05, **P o0.01, ***P o0.001 by Student’s t-test. (e) Whole-mount mammary
gland preparations (24 W) revealed hyperplasia in Ptpro− / −/MMTV-Erbb2 glands compared with littermate controls. The bottom panels showed
a Ptpro− / −/MMTV-Erbb2 gland with pervasive epithelial hyperplasia. (f) Average tumor volume was calculated after initiation of palpable
tumors. Error bars indicate s.e.m. (n = 6 in Ptpro− / −/MMTV-Erbb2, and 6 in Ptpro+/+/MMTV-Erbb2). *P = 0.043, two-sided paired t-test. (g) The box
plots of the weights of tumors harvested at 6 weeks are shown. *P = 0.047, two-sided paired t-test.

© 2016 Macmillan Publishers Limited
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Figure 2. Interaction of PTPRO with ERBB2 in SKBR3 cells. (a) Co-immunoprecipitation showed interaction between PTPRO and ERBB2. SKBR3
cells were incubated with or without heregulin (HRG). Immunoprecipitation (IP) was performed using either anti-PTPRO or anti-ERBB2
antibodies. Immunoblots of immunoprecipitates were showed with the antigens as labeled to the left. (b) Duolink in situ proximity ligation
assay (PLA) in SKBR3 cells. The top two ﬂuorescent micrographs showed the negative controls in which a non-speciﬁc immunoglobulins (IgG)
replaced either the anti-PTPRO or anti-ERBB2 antibody. Using both anti-PTPRO and anti-ERBB2 antibodies, positive reactions (Red) were
detected in cells transfected with scramble control small interfering RNA (siCtrl) while knocking down either ERBB2 or PTPRO with siERBB2 or
siPTPRO, respectively, abolished the signals. These results were representative of three independent experiments.

To examine the requirement of PTPRO phosphatase activity in
the growth of breast cancer cells, we mutated the catalytic
site (CS) of PTPRO23 and transfected this plasmid into two
ERBB2-positive SKBR3 and BT474 cell lines, which have low
PTPRO levels (Figures 4a and b). Transfection of wild-type PTPRO
inhibited the proliferation and colony formation of SKBR3 and
BT474 cells as compared with empty vector, whereas the CS
mutation of PTPRO only partially attenuated its inhibitory
activity on cell growth and colony formation (Figures 4c and
d). Flow cytometry studies showed a remarkable increase in the
percentage of cells in the G1 phase in PTPRO-expressing cells
compared with cells transfected with empty vector (control)
or the PTPRO-CS mutant (Figure 4e). Flow cytometry for
Annexin-V-FITC and PI staining did not show obvious difference
in apoptosis among these cells (Figure 4f). These ﬁndings
suggested that the enhancement of cell proliferation and cell
cycle induced by PTPRO deletion was mimicked by the loss of
PTPRO phosphatase activity.
Oncogene (2016) 1 – 13

ERBB2-dependent oncogenic signaling was antagonized by PTPRO
in breast cancer
We next investigated whether PTPRO could regulate ERBB2
phosphorylation and ERBB2-dependent signaling in genetic model,
MEFs derived from mice and human cancer cells. Results from the
immunoblotting and immunohistochemistry (IHC) studies revealed
an increased ERK1/2 (p44/42) phosphorylation as well as AKT
phosphorylation in Ptpro− / − mouse mammary tissues and tumors
as compared with wild-type controls, indicating the in vivo effects of
PTPRO on AKT/ERK signaling (Figures 5a and d and Supplementary
Figures 2A and B). In the same line of evidence, Ptpro deletion
enhanced ERBB2 signaling and activation of downstream mitogenactivated proteinkinase and phosphatidylinositol 3-kinase/AKT
signaling pathways in cultured MEFs overexpressing ERBB2 as
compared with wild-type control (Figures 5b and e). Conversely,
PTPRO overexpression in SKBR3 and BT474 breast cancer cells was
accompanied by reduced phospho-ERK and phospho-AKT signaling
as compared with vector control (Figures 5c and f), whereas
© 2016 Macmillan Publishers Limited
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Figure 3. Effects of Erbb2/Ptpro− / −MEFs on cell viability, cell proliferation and apoptosis. (a) Immunoblotting of two genotypic MEFs derived
from littermates, which were stably transfected with FUGW-Erbb2 vector or control vector. (b) Erbb2/Ptpro+/+ MEFs and Erbb2/Ptpro− / − MEFs
were inoculated in 96 wells for 24, 48 and 72 h, cell viability was measured by MTT assay. (c) Erbb2/Ptpro+/+ MEFs and Erbb2/Ptpro− / − MEFs cells
were seeded in a six-well plate and incubated for 2 weeks to allow colony formation (left). Quantitative determination of colony numbers
(right). (d) Cell cycle analysis by ﬂow cytometry in Erbb2/Ptpro+/+ MEFs and Erbb2/Ptpro− / − MEFs. The bar graphs show the relative quantity of
G1, G2 and S in the Erbb2/Ptpro+/+ MEFs compared with the Erbb2/Ptpro− / − MEFs. (e) Apoptosis was determined by ﬂow cytometry following
Annexin-V-FITC and PI dual labeling. Samples shown are representative of three independent experiments. Error bars indicate s.e.m. *Po 0.05,
**P o0.01 by Student’s t-test.

expression of PTPRO CS-mutant in SKBR3 cells did not impact the
activation status of ERK and AKT (Figures 5c and f). Therefore,
PTPRO phosphatase activity was required for its impact on ERBB2AKT-ERK signaling.
In accordance with above ﬁndings, correlation analysis of
clinical specimen of TMA demonstrated an inverse relationship
between PTPRO and the phospho-ERBB2/ERBB2 ratio, phosphoERK and phospho-AKT levels (PTPRO and phospho-ERBB2/ERBB2
ratio: P o0.001; PTPRO and phospho-ERK: P o0.001; PTPRO and
phospho-AKT: P o0.001; Figures 6a and b). Gene set enrichment
analysis of published human breast cancer expression proﬁles27
revealed that PTPRO expression was associated with reduced AKT
and ERK signaling gene signatures in ERBB2-positive patients
© 2016 Macmillan Publishers Limited

(Figure 6c). Together, these results suggested that PTPRO was an
important modulator for ERBB2–AKT–ERK axis both in experimental and clinically relevant settings.
Since Y1248 is an autophosphorylation site,28 Y1248phosphorylated ERBB2 might increase as total ERBB2 increases.
If the increase in phospho-Y1248 was merely due to increase in
total ERBB2, then the ratio of phospho-ERBB2 to total ERBB2
should remain similar. We generated two stable PTPROknockdown cells in PTPRO-high ZR75-1 cell line, named ZR75-1shPTPRO #1 and ZR75-1-shPTPRO #2. Immunoblotting showed
that both ZR75-1-shPTPRO #1 and ZR75-1-shPTPRO #2 cells had
increased phosphorylation of ERBB2 at Y1248 as compared with
ZR75-1-shCtrl both in the basal state and with heregulin
Oncogene (2016) 1 – 13
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stimulation. Importantly, the ratio of phospho-ERBB2 to total
ERBB2 noticeably changed upon knockdown of PTPRO, especially
when stimulated with heregulin (Supplementary Figure 3).

Oncogene (2016) 1 – 13

These experiments suggested that loss of PTPRO-mediated
dephosphorylation was the main cause of increase in phosphorylation at Y1248.

© 2016 Macmillan Publishers Limited
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PTPRO phosphatase activity was required for the endosomal
internalization of ERBB2
Given that phosphatases can regulate RTKs at multiple levels
through complex mechanisms,29,30 we thus next investigated
whether PTPRO phosphatase activity could control ERBB2
subcellular compartmentalization and internalization and thereby
repressed ERBB2 oncogenic function. Flow cytometry assay
showed that cell surface ERBB2 was decreased in PTPROoverexpressing cells, whereas the amount of the cell surface
ERBB2 was not obviously altered in CS mutation cells as compared
with empty vector-transfected cells (Figure 7a). These results
suggested that the internalization and trafﬁcking of ERBB2 might
be controlled by PTPRO phosphatase activity to repress ERBB2
signaling.
Internalization and degradation are known mechanisms for
many RTKs’ downregulation.31 However, little is known for the role
of dephosphorylation on the internalization of ERBB2.9,11,16,17
To determine whether the observed PTPRO-mediated downregulation of ERBB2 might result from accelerated protein
degradation, SKBR3 cells were treated for 0–24 h with the
translation inhibitor cycloheximide to block de novo protein
synthesis. PTPRO overexpression remarkably accelerated degradation of ERBB2 (Figure 7b). The half-life of ERBB2 protein decreased
to 10.2 h as opposed to 19.6 h in control cells. However, this ERBB2
degradation appeared not to involve proteolysis through the
ubiquitin-proteasome system as a proteasome inhibitor MG132
did not attenuate the PTPRO-induced degradation of ERBB2
(Figure 7b). In contrast, a lysosome inhibitor chloroquine
abolished ERBB2 degradation in the presence of PTPRO
overexpression (Figure 7b), suggesting that the acceleration of
ERBB2 degradation by PTPRO was primarily through lysosomal
degradation. In corroboration with this evidence, confocal
immunoﬂuorescence microscopy demonstrated that the accumulation of ERBB2 increased in endosomes (as shown by
co-localization with EEA1) in PTPRO-overexpressing SKBR3 cells
(Figure 7c, left panels), whereas CS mutation did not increase such
accumulation compared with empty vector control (Figure 7c, left
panels). Further, increased ERBB2 was detectable in lysosomes (as
shown by LAMP-1 co-localization) of PTPRO-overexpressing cells
compared with empty vector or CS mutant cells (Figure 7c, right
panels). These data suggested that PTPRO phosphatase activity
controlled the endocytotic degradation, contributing to ERBB2
downregulation.
To further address whether phosphorylation of Y1248 was
determinant for the lysosomal degradation of ERBB2, we used
site-directed mutagenesis to generate dephosphorylated-Y1248mimicking (that is, mutated to phenylalanine (Y1248F)) and
phosphorylated-Y1248-mimicking (that is, mutated to glutamate
(Y1248E)) mutants.32 In an ERBB2-negative cell line with low
endogenous PTPRO expression (MDA-MB-231), we co-transfected
PTPRO-WT or PTPRO-CS with ERBB2-WT or mutants of Y1248, and
examined the cellular distribution of ERBB2 Y1248 mutants
(Supplementary Figure 4A). As analyzed with confocal immunoﬂuorescence microscopy, dephosphorylation-mimicking mutant
of ERBB2, Y1248F, showed co-localization with an endosomal
marker (EEA1) and a lysosomal marker (LAMP-1), which was

comparable to the results for cells transfected with ERBB2-WT and
PTPRO-WT plasmids (Supplementary Figures 4B and C, left panels).
Although the loss of phosphatase activity in PTPRO-CS mutant
blocked the co-localization with endosomal and lysosomal
markers, this had no effect on the dephosphorylation-mimicking
mutant (Supplementary Figures 4B and C, right panels). In
contrast, the phosphotyrosine-mimicking mutant (Y1248E) did
not co-localize with either endosomes or lysosomes in the
presence of ectopic expression of PTPRO-WT or PTPRO-CS
(Supplementary Figures 4B and C). Together, these data demonstrated that the phosphorylation status of Y1248-regulated
endosomal internalization and lysosomal degradation of ERBB2,
and dephosphorylation of Y1248 was the mechanism by which
PTPRO phosphatase activity regulated these changes in ERBB2.
Therapeutic potentials of epigenetic reexpression of PTPRO for
suppressing ERBB2-positive breast cancer
We and others have previously documented PTPRO hypermethylation in breast cancer.24,33 However, the PTP-associated gene
inactivation involved in tumorigenesis and tumor progression may
be due to point mutation or deletion, in addition to promoter
hypermethylation.34,35 To test this, we examined the frequency of
genomic mutation or deletion in the coding region of PTPRO.36 We
analyzed data from the cBioPortal for Cancer Genomics (http://
cbioportal.org).37 The incidence of genomic PTPRO mutation was
0.4% of 962 cases (TCGA), 0.2% of 482 cases (TCGA pub) and 1% of
100 cases (Sanger); the rates of PTPRO deletion were 0.6% of 962
cases (TCGA), 0.0% of 482 cases (TCGA pub) and 0.0% of 100 cases
(Sanger; Supplementary Figure 5A), whereas PTPRO hypermethylation inversely associated with PTPRO mRNA expression
(Supplementary Figure 5B). Given that exon 1 and promoter
regions of PTPRO contain typical CpG islands (Figure 8a), we
performed methylation-speciﬁc PCR using genomic DNA extracted
from 37 breast cancer specimens and their respective adjacent
non-tumor tissues. In all, 25 (67.6%) of 37 cancer specimens
exhibited a complete or partial DNA methylation, whereas 12
(32.4%) of the 37 adjacent non-tumor tissues had partial
methylation and no methylation in the remaining non-tumor
samples (Supplementary Figure 6A). Furthermore, the PTPRO
promoter was hypermethylated in seven breast cancer cell lines,
but not in immortalized non-cancerous MCF-10A and normal
human mammary tissues (Supplementary Figure 6B). We quantiﬁed the relative levels of promoter methylation and protein
expression by measuring densitometry of the corresponding
bands using software ‘Quantity one’. Pearson’s correlation analysis
showed that there was an inverse linear relationships between
promoter methylation and protein expression of PTPRO (r = -0.965;
P = 0.002; Supplementary Figure 6C). These results suggested that
promoter hypermethylation, instead of genomic mutation and
deletion, was the primary mechanism responsible for repressed
PTPRO expression.
We next investigated the therapeutic potential that reexpression
of PTPRO by epigenetic modiﬁcation could suppress ERBB2positive breast cancer. The DNA methyltransferase inhibitor
5’-aza-2’-deoxycytidine (5-aza-dC) was used to block promoter

Figure 4. Effect of PTPRO overexpression on cell viability, cell proliferation and apoptosis in ERBB2-overexpressing cell lines. (a) Levels of
PTPRO protein in 7 breast cancer cell lines examined by immunoblotting. Normal kidney and MCF-10A cells were positive references.
(b) Immunoblotting of breast cancer cells transfected with PTPRO-WT vector and mutant PTPRO-CS vector. (c) PTPRO-expressing cells had
lower growth rates than that in empty vector and CS mutation of PTPRO cells as indicated by MTT assay. (d) PTPRO-expressing cells had lower
clone formation ability than that in empty vector and CS mutation of PTPRO cells. (e) A remarkable increase in percentage of cells in G1 phase
in PTPRO-expressing cells compared with cells transfected with empty vector or PTPRO-CS mutant cells as assayed by ﬂow cytometry (left). The
bar graphs showed the percentage of cells in G1, G2 and S phase (right). (f) Flow cytometry for Annexin-V-FITC and PI staining did not show
visible difference in apoptotic cell distribution among these cells. Samples shown are representative of three independent experiments. Error
bars indicate s.e.m. *P o0.05, **P o0.01, ***P o0.001 by Student’s t-test.
© 2016 Macmillan Publishers Limited
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Figure 5. PTPRO modulates ERBB2 and downstream signaling through ERK/AKT pathways in breast cancer. (a) Immunoblots of mammary
tissues from mice are shown with the antigens labeled on the left. ERBB2 phosphorylation was increased in mammary glands (4 months of
age) and tumors (7 months of age) following Ptpro deletion in Erbb2 transgenic mice compared with littermate controls. (b) ERBB2
phosphorylation was increased in Erbb2/Ptpro− / − MEFs compared with littermate controls. (c) ERBB2 phosphorylation was decreased in PTPROoverexpressing breast cancer cells rather than in PTPRO mutant (CS) cells. (d) Immunoblots of mammary tissues from mice are shown with the
antigens labeled on the left. ERK and AKT phosphorylation were increased in mammary glands (4 months of age) and tumors (7 months of
age) following Ptpro deletion in Erbb2 transgenic mice compared with littermate controls. (e) ERK and AKT phosphorylation were increased in
Erbb2/Ptpro− / − MEFs compared with Erbb2/Ptpro+/+ MEFs. (f) ERK and AKT phosphorylation were decreased in PTPRO-overexpressing breast
cancer cells rather than in PTPRO mutant (CS) cells.
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Figure 6. PTPRO expression correlated inversely with p-ERBB2, p-ERK and p-AKT in human breast cancer tissues. (a) Representative
immunohistochemistry images for PTPRO, ERBB2, p-ERBB2, p-ERK and p-AKT in ﬁve serial sections of the same tumor from two primary
human breast cancer specimens (magniﬁcation, the top panels: × 100; the bottom panels: × 400). (b) Percentage of samples showing low or
high p-ERBB2/ERBB2 ratio, p-ERK and p-AKT expression (from top to bottom) relative to the levels of PTPRO in 180 cases of human breast
cancer samples. (c) Gene set enrichment analysis showing inverse correlations between PTPRO expression and an AKT gene signature
(CREIGHTON_AKT1_SIGNALING_VIA_MTOR_UP) and an ERK gene signature (BIOCARTA_ERK_PATHWAY) in a published cohort of breast cancer
patients (GSE1456; the top tertile (48 cases) of ERBB2 mRNA expression was assumed to be ERBB2-positive tumors). ***P o0.001, Spearman's
rank test. FDR, false-discovery rate q value; Neg., negative; NES, normalized enrichment score; Pos., positive.

methylation in BT474 and SKBR3 cells. 5-aza-dC treatment of cells
decreased methylation, leading to reexpression of PTPRO
(Figure 8b). Further, the demethylation treatment using 5-aza-dC
effectively reduced the ERBB2-induced cell growth and transformation as evidenced by colony formation (Figures 8c and d), and
knockdown of PTPRO expression using small interfering RNA
(Figure 8c) diminished the effect of 5-aza-dC (Figure 8d). Thus, the
effect of 5-aza-dC was at least in part mediated by reexpression of
PTPRO. Moreover, ERBB2-dependent oncogenic signaling was
blocked by demethylation treatment using 5-aza-dC (Figure 8e).
Taken together, our data strongly argued that reexpression of
PTPRO by treatment with 5-aza-dC could suppress ERBB2-positive
breast cancer.
DISCUSSION
Although prior epidemiologic, bioinformatics data and cellular
studies are suggestive of a tumor-suppressor function for PTPRO
in breast cancer,24,25 deﬁnitive in vivo evidence has been lacking
until this study. We used a genetic approach by breeding Ptpro© 2016 Macmillan Publishers Limited

null mice with MMTV-Erbb2 transgenic mice to characterize the
role of Ptpro in breast tumorigenesis and cancer progression. Our
in vivo results together with in vitro data, ﬁrmly establish Ptpro as a
tumor-suppressor gene. To exclude the possibility that the noted
phenotypes in Ptpro knockout mice could be due to effects of loss
of Ptpro in non-breast tissue, we performed transplantation of
mammary cells derived from mice. Data derived from tumor cell
transplantation strongly argue that the accelerated tumor growth
observed in Ptpro− / −/MMTV-Erbb2 mice is directly due to loss of
Ptpro function within the breast cancer cells themselves.
It was unclear whether PTPRO repressed ERBB2-positive cancer
by blocking the key oncogenic signaling downstream of ERBB2.
Using non-malignant immortalized MCF-10A cells, a prior study
showed that neither ERK nor AKT was activated by PTPRO
downregulation.25 However, we demonstrated that PTPRO regulated AKT and ERK activation in ERBB2-induced cancer cells using
genetic mouse model, MEFs derived from transgenic mice, human
cancer cells and patient specimens and bioinformatics data
mining. The contrasting results from two studies may reﬂect the
difference between non-malignant cells used in prior study and
Oncogene (2016) 1 – 13
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Figure 7. PTPRO reduced ERBB2 half-life. (a) Cell surface ERBB2 expression was reduced in PTPRO-expressing cells than that in empty vector
and CS mutation of PTPRO cells as indicated by ﬂow cytometry. Normal rabbit IgG as a control. Samples shown are representative of three
independent experiments. Error bars indicate s.e.m. ***P o0.001 by Student’s t-test. (b) PTPRO-expressing cells were incubated with 20 μg/ml
cycloheximide (CHX) for 0, 2, 4, 8, 12 or 24 h plus 10 μmol/l of MG132 or 100 μmol/l of chloroquine. ERBB2 and β-tubulin were detected by
immunoblotting and measured by integrated optical density. Half-life (h): Vector: 19.6; PTPRO: 10.2; PTPRO+MG132: 11.8; PTPRO+Chloroquine:
18.0. The log relative optical density (OD) of a band is deﬁned as the log10 (integrated OD of ERBB2/integrated OD of ERBB2 at time 0 h) - log10
(integrated OD of β-tubulin/integrated OD of β-tubulin at time 0 h). (c) PTPRO enhanced endocytosis of ERBB2. Representative confocal
ﬂuorescent micrographs are shown. The detected antigens were labeled at the top: ERBB2 and EEA1 (an early endosomes). Areas of colocalization were highlighted using Image J. (d) PTPRO-induced co-localization of ERBB2 and lysosomes. The experiment was similar to (c)
except that LAMP-1 (a lysosomal maker) was examined instead of EEA1. DAPI, 40 -6-diamidino-2-phenylindole.

cancer cell systems used in our study. Our studies ﬁrmly establish
a functional association between PTPRO phosphatase activity and
ERBB2 oncogenic signaling using multiple experimental systems.
We have veriﬁed that PTPRO deﬁciency promotes ERBB2-driven
breast tumorigenesis via activating oncogenic signaling and the
phosphatase catalytic site of PTPRO is required for its effect on
ERBB2-AKT-ERK signaling. Our studies also highlight a new
conceptual framework in which PTPRO downregulates tyrosine
phosphorylation of multiple oncogenic pathways in breast
carcinogenesis.
Several PTPs have been previously reported to either positively
or negatively regulate ERBB2 tyrosine phosphorylation.11–17
However, structural analysis of the tyrosine phosphatome showed
that PTPRO is distinct in structure, catalytic activity and substrate
recognition.38 Although ERBB2 has been reported to be the
Oncogene (2016) 1 – 13

substrate of PTPRO,25 the speciﬁc tyrosine residue that is
selectively catalyzed by PTPRO remains unknown. In this study,
our co-immunoprecipitation experiment along with the results
derived from in vivo, cultured cells and clinical specimen conﬁrm
that PTPRO dephosphorylates ERBB2 at Y1248. Among the
multiple ERBB2 tyrosine phosphorylation sites, Y1248 has been
documented to be biologically important and clinically signiﬁcant.
Y1248 has a role in cell differentiation as MUC4/SMC forms a
complex with ERBB2, which leads to Y1248 phosphorylation39 and
translocation of ERBB2 to the apical surface of polarized epithelial
cells.40 In breast cancer, activated Y1248 ERBB2 was detected in
20% of patients,41 and the expression of this phosphorylation site
is highly speciﬁc for ERBB2 gene ampliﬁcation.42 Importantly,
phosphorylation of Y1248 shows prognostic value; increased
ERBB2 phosphorylation of Y1248 represents a lower 5-year
© 2016 Macmillan Publishers Limited
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Figure 8. 5’-Aza-2’-deoxycytidine (5-aza-dC) reduced cell growth that was due to low PTPRO expression. (a) The methylation-speciﬁc PCR (MSP)
region of the PTPRO gene CpG island. (b) Restored expression of PTPRO by treatment of 5-aza-dC. Expression and methylation analysis of PTPRO
in BT474 and SKBR3 cell lines incubated with or without 5-aza-dC. GAPDH was used as an internal loading control. M, methylated; U,
unmethylated. (c) Immunoblotting revealed that PTPRO was efﬁciently knocked down by the treatment of siPTPRO #1 or siPTPRO #2. (d) siPTPRO
#1 or siPTPRO #2 cells were treated with and without 5 μM 5-aza-dC for 10 days to allow colony formation (left). Quantitative determination of
colony numbers (right). (e) Combination of 5-aza-dC and siPTPRO treatment. SKBR3 cells were treated with siPTPRO #1 for 48 h before incubation
with 5 μM 5-aza-dC. Cell lysates were immunoblotted with the labeled antibodies on the left. **Po0.01, ***Po0.001 by Student's t-test.

Figure 9. Schematic summary of the role of PTPRO in ERBB2-driven breast carcinogenesis: PTPRO is regulated epigenetically by methylation.
PTPRO suppresses ERBB2 signaling through both tyrosine dephosphorylation of ERBB2 at Y1248 and endocytotic internalization and
subsequent degradation.

disease-free survival rate than patients with low levels phosphorylation of Y1248,43 and Y1248 phosphorylation is an independent
predictors of progression-free survival.41 Of note, Y1248 is known
to activate mitogen-activated proteinkinase and mediate cell
proliferation,42,44,45 which supports our ﬁndings that PTPRO
regulates ERBB2-induced ERK activation and cancer cell
© 2016 Macmillan Publishers Limited

proliferation. We also used proximity ligation assay (Duolink) to
provide the ﬁrst evidence that PTPRO and ERBB2 directly bind
each other on the cell membrane and in the cytoplasm.
Signaling of RTKs can be regulated at multiple levels. At the
receptor level, the quantity of RTKs on the cell surface can be
controlled by post-translational modiﬁcation (for example,
Oncogene (2016) 1 – 13
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dephosphorylation), endocytosis and then degradation via lysosomal or ubiquitin-proteasome system.12,46 Nevertheless, protein
degradation of ERBB2 is poorly understood.16,47 In this study, we
have found that PTPRO regulates the internalization of ERBB2 via
endocytosis and subsequent lysosomal degradation. Further, we
have revealed that PTPRO catalytic activity is required for the
internalization. Thus, PTPRO phosphatase activity is critical for
both dephosphorylation and internalization, which is eventually
responsible for PTPRO-mediated ERBB2 downregulation (Figure 9).
PTPRO is located on chromosomal region 12p12.3, which is
characterized by loss of heterozygosity in different types of
cancers.20–23 In contrast to several other PTPs,34,48,49 we have
found that PTPRO mutation and deletion are rare in human breast
cancer. Given our previous result of high prevalence of PTPRO
promoter hypermethylation in breast cancer,24 we conclude that
promoter hypermethylation is the major mechanism for PTPRO
gene silencing in breast cancer.
Promoter hypermethylation provides a promising molecular
target for epigenetic therapy of cancer. As such, we have found
that reexpression of PTPRO by treatment with 5-aza-dC can
effectively blocked ERBB2-dependent oncogenic signaling as well
as tumor growth in cancers with PTPRO silencing. Based on the
ﬁndings in this study, it is tempting to speculate that reactivation
of PTPRO expression through epigenetic modiﬁcation may be
further explored in clinical settings either alone or in combination
with targeted therapy. Because loss of PTPRO expression has also
been reported in hepatomas,21,50 colon cancer22,51 and lung
cancer,23 we believe that our molecular insights are likely to be of
a broad signiﬁcance in cancer at-large.
In summary, these studies have established the role of PTPRO as
a tumor suppressor in breast cancer in vivo. The model of
epigenetic control of PTPRO-mediated ERBB2-AKT-ERK pathway
largely reﬂects the clinical conditions in breast cancer. PTPRO
phosphatase activity is required for dephosphorylation, endocytosis and lysosomal degradation of ERBB2, leading to the
downregulation of its downstream signaling. The discovered
importance of PTPRO in this study will shed light on how to target
ERBB2-driven cancers by either selecting the right patients for
personalized cancer therapy or designing further therapeutic
strategies or both of such approaches.
MATERIALS AND METHODS
Mice
The Ptpro− / −mice, gifts from Dr Bixby, University of Miami, and FVB/N mice
carrying the Erbb2 gene (MMTV-Erbb2) were obtained from Jackson
Laboratories. All mice were maintained and bred at the Animal Center of
Shantou University Medical College. Ptpro− / − mice were bred with wildtype FVB/N mice for 10 generation to obtain Ptpro− / −mice with 99.90%
FVB/N background, which took about 2 years, and their female offspring
were paired with male MMTV/Erbb2 transgenic mice with a FVB strain
background. Age-matched Ptpro+/+/MMTV-Erbb2 and Ptpro− / −/MMTVErbb2 virgin mice with 99.95% FVB/N genetic background (11 generation
backcross to FVB/N strain) were used for further experiments. Littermates
with both genotypes were used in the same phenotypic alterations
whenever it was possible. Their genotypes were identiﬁed by PCR analyses
of tail DNA samples, as described previously.52,53 The primers of mice
genotypes analysis are listed in Supplementary Table 2. Animals were
housed in pathogen-free conditions at the Animal Center of Shantou
University Medical College in compliance with Institutional Animal Care
and Use Committee regulations (SUMC2014-148). All animal experiments
were performed according to protocols approved by the Animal Care and
Use Committee of the Medical College of Shantou University.

Patient specimens
Surgically treated female breast cancer patients (n = 180) with conﬁrmed
pathology of invasive ductal carcinoma were collected for preparation
of tissue microarray (see Supplementary Information) for IHC and
methylation-speciﬁc PCR. Breast cancer tissues were obtained from the
Oncogene (2016) 1 – 13

patients when undergoing surgical treatment at the Department of
Surgery, Cancer Hospital of Shantou University Medical College, during the
period from 2010 to 2013. All patients received primary treatment by
surgery followed by adjuvant radiotherapy, chemotherapy or hormone
therapy. A total of 180 primary breast cancer patients contained all
subtypes of breast cancer (that is, luminal A, luminal B, ERBB2-enriched and
basal-like), including 60 ERBB2-positive patients. Clinical research protocols
of this study were reviewed and approved by the Institutional Review
Board and the Ethics Committee of Cancer Hospital of Shantou University
Medical College (IRB serial number: # 04–070). Written informed consents
were obtained from patients in accordance with principles expressed in
the Declaration of Helsinki.
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